Sökning: "prognostic marker"
Visar resultat 6 - 10 av 245 avhandlingar innehållade orden prognostic marker.
6. RNA-based Prognostic Markers in Chronic Lymphocytic Leukemia
Sammanfattning : Chronic lymphocytic leukemia (CLL) is a heterogeneous disease where a significant proportion of patients will develop an aggressive disease. Today, the mutational status of the immunoglobulin heavy variable (IGHV) genes is one of the strongest prognostic markers in CLL, where unmutated IGHV genes correlate with poor outcome. LÄS MER
7. Prognostic markers and DNA methylation profiling in lymphoid malignancies
Sammanfattning : In recent years, great progress has been achieved towards identifying novel biomarkers in lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), at the genomic, transcriptomic and epigenomic level for accurate risk-stratification and prediction of treatment response. In paper I, we validated the prognostic relevance of a recently proposed RNA-based marker in CLL, UGT2B17, and analyzed its expression levels in 253 early-stage patients. LÄS MER
8. Telomere length : dynamics and role as a biological marker in malignancy
Sammanfattning : Telomeres are protective structures at the end of our chromosomes, composed of multiple repeats of the DNA sequence TTAGGG. They are essential for maintaining chromosomal stability by preventing damage and degradation of the chromosome ends. LÄS MER
9. Assessment of Novel Molecular Prognostic Markers in Chronic Lymphocytic Leukemia
Sammanfattning : The clinical course of chronic lymphocytic leukemia (CLL) is highly heterogeneous, which has prompted the search for biomarkers that can predict prognosis in this disease. The IGHV gene mutation status and certain genomic aberrations have been identified as reliable prognostic markers of clinical outcome for this disorder. LÄS MER
10. DNA methylation as a prognostic marker i acute lymphoblastic leukemia
Sammanfattning : Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Most ALL cases originate from immature B-cells (BCP-ALL) and are characterized by reoccurring structural genetic aberrations. These aberrations hold information of the pathogenesis of ALL and are used for risk stratification in treatment. LÄS MER